In a groundbreaking announcement, the FDA revealed on Friday that it will provide an accelerated review process for three psychedelic drugs aimed at combatting mental health issues, particularly depression. This initiative reflects the Trump administration's commitment to exploring unconventional treatment methods.
Last weekend, President Donald Trump signed an executive order instructing the FDA and other federal agencies to expedite access to psychedelics, which are still classified as illegal under federal law.
The FDA has issued priority review vouchers to two firms researching psilocybin—the active component in magic mushrooms—for severe depression cases. Another company was awarded a voucher for methylone, related to MDMA, targeted for treating PTSD. The FDA hasn’t disclosed the names of these companies in its announcement.
These vouchers streamline the review processes, aiming to lessen the review period from several months to mere weeks, although they do not ensure eventual approval.
This recent approach signifies growing public support for psychedelics, particularly among Trump’s base, which includes many veterans advocating for the healing potential of these substances. The move is part of a larger initiative prompted by Health Secretary Robert F. Kennedy Jr., a proponent of the Make America Healthy Again movement.
Last summer, Kennedy expressed to Congress a targeted effort to make psychedelics readily available for challenging psychiatric conditions within a year. Notably, some of his closest aides have been vocal advocates for these drugs.
The specialization shown towards psychedelics by the FDA is expected to draw heightened scrutiny regarding its expedited drug review processes. Critics, including some democratic members of Congress, have raised concerns that such vouchers have been provided to companies favored politically by the White House.
Moreover, the FDA has given the green light for the initial testing of a drug related to ibogaine, a potent psychedelic derived from an African shrub, for treating alcohol use disorder. Despite known risks associated with ibogaine—such as potential dangerous heart rhythms—there is significant interest in its use as a remedy for trauma and addiction.
Trump's engagement on this issue notably includes input from influential personalities such as podcaster Joe Rogan, who has openly discussed ibogaine and its potential therapeutic effects on his platform. Rogan's prior endorsement of Trump is believed to have played a pivotal role in the election dynamics.
Overall, with psychedelic substances historically categorized as Schedule I drugs—deemed to have no accepted medical use—the current landscape indicates a transformative shift in both public and legislative attitudes towards their potential therapeutic applications.
